Investigating how mitochondrial signaling affects cell death in Alzheimer's disease
Official title: Contribution of Mitochondrial Associated Membrane (MAM) Signaling to Neurodegeneration
Funded at Yale University · NIH-10890252 · Data updated 2026-11-12
This study is looking at how a protein called BOK affects cell death in Alzheimer's disease by helping to manage calcium levels in brain cells, which could lead to new ways to treat this condition.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | April 15, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $335,000 |
| NIH project number | 1R03AG087416-01 |
| Project ID | NIH-10890252 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies.
✕Less likely to help
Patients with non-tauopathies or other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on understanding the role of mitochondrial-associated membranes (MAMs) in the cell death processes associated with Alzheimer's disease. By examining how a specific protein, BOK, influences calcium transfer between the endoplasmic reticulum and mitochondria, the study aims to uncover potential therapeutic targets for neurodegenerative conditions. The researchers will analyze the effects of tau protein accumulation on neuronal cell death and how BOK's regulation of MAMs contributes to this process. This investigation could lead to new insights into the mechanisms of Alzheimer's disease and potential interventions.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that slow down or prevent the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results in targeting mitochondrial signaling pathways for neurodegenerative diseases, suggesting that this approach could be effective.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Katz, Samuel G — Yale University
- Study coordinator: Katz, Samuel G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.